Journal article
High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes
M Chao, D Bolton, D Lim Joon, Y Chan, N Lawrentschuk, H Ho, S Spencer, J Wasiak, M Guerrieri, D Ow, A Troy, T Pham, S Sengupta, A Tan, K McMillan, G Koufogiannis, F Foroudi, M Ng, V Khoo
Journal of Medical Imaging and Radiation Oncology | WILEY | Published : 2019
Abstract
Introduction: To examine the long-term outcomes of high dose rate brachytherapy boost (HDR-BT) combined with external beam radiotherapy (EBRT) for intermediate and high-risk prostate cancer patients. Methods: Data from 95 patients who underwent combined EBRT (50.4 Gy) and HDR-BT to the prostate between 2010 and 2017 were retrospectively analysed. Biochemical progression free survival (bPFS), local recurrence free survival (LRFS), metastatic free survival (MFS) and overall survival (OS) were estimated using Kaplan–Meier method. Regression analysis was conducted to identify important predictors of outcomes. Results: A total of 24 patients received an initial HDR-BT dose of 18 Gy in three fract..
View full abstract